Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Edessa

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Edessa head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 170 · Grade C

Edessa

Visit Edessa Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 70 on our six-factor Brief Score — One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.

That doesn't make Edessa a bad call — it's best for a six-month committer, or a reader willing to click past the front page to the table with the real monthly rate. Weigh the six factors below against your own priorities before you decide.

Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
64
Supply Reliability
95
72
Transparency
90
66
Access Breadth
93
82
Clinical Oversight
92
72
Track Record
88
66
CoreAge RxBrief Score 94 · 70Edessa

Price, coverage & the tracker

CoreAge RxEdessa
Brief Score94/100 (A)70/100 (C)
Semaglutide$99/mo only on a 12-month plan paid in full ($1,188 in one charge); month-to-month rate not published$179/mo month-to-month injectable (compounded)
Tirzepatide$149/mo only on a 12-month plan paid in full ($1,788 in one charge); month-to-month rate not published$239/mo month-to-month (compounded)
CoverageUS only; restrictions by state, confirmed at intakeNot published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: Headline unchanged for a third straight cycle. The $99 and $149 are the 12-month prepay rates; CoreAge publishes no month-to-month price.

Edessa: New to the tracker on 13 September 2026, read live off the provider's own pages that day rather than taken on trust. There is no earlier reading here to compare against, so the direction is "new" rather than stable — a first observation is not a trend. The gap to watch is between the two surfaces: the front page quotes $135, $199 and $209 while the product pages behind them quote $179, $229 and $239 for the same three products month to month.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.